News

First U.S. patient enrolled in GORE® VIAFORT Vascular Stent pivotal study.

The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.

FLAGSTAFF, Ariz. (October 28, 2022) — W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular Stent as part of the recently initiated GORE VIAFORT Device  Pivotal Clinical Study, (i.e., prospective, multicenter, non-randomized, single-arm study NCT05409976) for the treatment of inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement. 

Gore, a global material science company dedicated to transforming industries and improving lives, announce the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

FLAGSTAFF, Ariz. (APRIL 12, 2022) — Gore Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device). The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The TAMBE Device is the third Breakthrough Device in the company’s aortic endovascular portfolio to date, following the GORE® TAG® Thoracic Branch Endoprosthesis and the GORE® Ascending Stent Graft, two other investigational devices being developed.

FLAGSTAFF, Ariz. (JAN. 19, 2022) — W. L. Gore & Associates (Gore) today announced that the GORE® CARDIOFORM Septal Occluder has achieved 10 years of clinical use, treating patients through clinical studies and commercially in approved indications globally.*,† With more than 50,000 devices sold and zero reported cardiac erosions,‡ (Data on file. July 2011-November 2021; W. L. Gore & Associates, Inc.) this innovative technology from Gore offers physicians a safe option to treat patients with atrial septal defects (ASD) and patent foramen ovale (PFO).

FLAGSTAFF, Ariz. (August 19, 2021) — W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

FLAGSTAFF, Ariz. (March 11, 2021)— W. L. Gore & Associates (Gore), today announced that Gore REDUCE Study long-term follow-up results were published in the March 2021 issue of The New England Journal of Medicine (NEJM), highlighting the benefits of patent foramen ovale (PFO) closure. The extended follow-up data further supports the use of GORE CARDIOFORM Septal Occluder in long-term recurrent stroke prevention.

FLAGSTAFF, Ariz. (November 18, 2020) — W. L. Gore & Associates, Inc. (Gore), a global leader in providing solutions for cardiovascular disease, today announced encouraging clinical results from its early feasibility study evaluating the safety and performance of its pulmonary valved conduit, an investigational device. Six-month data for 16 patients enrolled across three sites in the United States were presented in a moderated poster session during the American Heart Association Virtual Scientific Sessions from November 13-17, 2020. The poster, P148, is titled, Early Results of a Novel ePTFE-based Pulmonary Valved Conduit in a Pediatric Patient Population.

FLAGSTAFF, Ariz – September 22, 2020 – As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced the U.S. launch of the lower profile, large diameter GORE® VIABAHN® Endoprosthesis.